5-FU single high dose infusion in multimodal therapy for head and neck cancer.

概要

論文の詳細を見る
Twenty-five patients with cancer of the head and neck were treated with high dose 5-FU infusion alone or as part of multimodal cancer treatment program. The infusion dose was 1500mg/24 hours for 120 hours via a peripheral vein. The courses were repeated at 2-3 week intervals. The tumor response and clinical effect of 5-FU high dose chemotherapy were evaluated in 12 patients who received 5-FU infusion alone. In the 10 patients with previously untreated epidermoid cancer, tumor response was apparent in 6 (1 had complete response and 5 partial response). In 9 of the 10 epidermoid cancer patients 5-FU was clinically effective and proved to be useful in further treatment as a part of multimodal therapy. Mild leukopenia, stomatitis, diarrhea and vasculitis/pigmentation were prominent side effects, but they could be tolerated by all 25 patients, even those with far-advanced cancer. This chemotherapy could be combined with radiotherapy. The results demonstrate that 5-FU alone in high dose infusions can play a role in preoperative induction chemotherapy and in multimodal cancer therapy.
耳鼻咽喉科臨床学会の論文